Genocea Biosciences, Inc (GNCA) is a publicly traded biotechnology company founded in 2006 that focuses on what they describe as the “T cell revolution” to develop new approaches when it comes to the development of therapies aimed at utilizing the patient’s own T cells to various viruses and cancers. To get an understanding of this company, we need to look some key elements of how the products that are in development have viability within the marketplace and that the data that shows, not only, that the proof of concept is sound but that data shows that GNCA sets and meets its target goals.
Firstly, to set a contextual understanding for the work that GNCA is doing and the methods that they are using we have to look at their mission statement.…show more content… GNCA saw its highest growth rate (in a year) of 7.1% on April 20, 2017 to $7.10, a share, but then dropped in the sequential weeks to a current rate of $6.11 as of May 15, 2017 (Fig 1). It should be noted that GNCA originally debuted its IPO at over $22.45 per share in February 24, 2014 so this fluctuation of high gains and losses seems to be a trend. The Following figures (Fig 2 & 3) is a breakdown of the First Quarter 2017 Financial Results released by Genocea on May 4, 2017.Looking at the first quarter 2017, GNCA is also showing mounting costs in Research and development which expanded about $2.4 million dollars to be currently at a total of $9.7 million. Research and Development are not the only mounting expenses, Administrative and general expenses have also raised in anticipation of the Phase 3 clinical program for its flagship product GEN-003. However the net loss GNCA is showing is expected to be $13.7 million compared to the first quarter in 2016; But as GNCA stated “The expansion (of costs) was driven by higher remuneration, counseling and administration costs in support of the GEN-003 program and increments in assembling costs identified with supply for Genocea's expected Phase 3 clinical program.” That loss can be calculated as to a 48 cents per share although it should be noted that shares for Genocea Biosciences have expanded about 53 percent since the start of the 2017 with a 12 month overall gain of 61 percent
